Tianjin Pharmaceuticals Da Ren Tang's (SGX:T14) net attributable profit to owners during the first quarter of the year jumped by 13% to 423.8 million yuan from 374.2 million yuan a year earlier, according to a Wednesday filing with the Singapore Exchange.
Shares of the pharmaceutical company rose nearly 5% in Thursday trading.
Earnings per share came in at 0.55 yuan compared with 0.49 yuan in the year-ago period.
Revenue increased by 4% year over year to 1.52 billion yuan from 1.46 billion yuan, backed by increased revenue from major product lines.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments